pubmed.ncbi.nlm.nih.gov

Non-diabetic Glucose levels and Cancer Mortality: A Literature Review - PubMed

Review

Non-diabetic Glucose levels and Cancer Mortality: A Literature Review

Eiichi Kakehi et al. Curr Diabetes Rev. 2018.

Abstract

Background: Although diabetes mellitus is a risk factor for cancer, the relationship of an increased glucose concentration at a non-diabetic glucose level with cancer mortality is yet to be determined.

Objective: The aim was to observe whether an increased glucose concentration and/or glucose intolerance at the non-diabetic glucose level can predict cancer mortality.

Methods: Population-based prospective cohort studies evaluating cancer mortality at the non-diabetic level (defined as fasting plasma glucose <7.0 mmol/L and two-hour plasma glucose <11.1mmol/L following an oral glucose tolerance test) were collected via a PubMed search with an additional Google scholar search between 1 January 1966 and 31 July 2016.

Results: We identified seven studies, which met the defined criteria. Studies examining fasting/casual states indicated an increase in cancer mortality with a slight increase in fasting/casual glucose levels in men in particular. Not all, but some studies using a glucose tolerance test indicated an increase in cancer mortality with impaired glucose tolerance/prediabetes. Concerning cause-cancer mortality, glucose intolerance states appeared to have an increase in mortality, particularly due to the stomach, liver and pancreatic cancers.

Conclusion: In these studies reviewed, cancer mortality increased in individuals with an increased glucose concentration and an increased potential was seen in those patients with glucose intolerance even at non-diabetic glucose levels. The outcome of these findings is promising and forms the basis for further studies to directly address the relevance of increased (non-diabetic) glucose and glucose intolerance as a prognostic indicator of cancer mortality.

Keywords: Non-diabetics; impaired fasting glucose; impaired glucose tolerance; malignancy; prediabetes; prospective cohort study..

PubMed Disclaimer

Cited by

Pancreatic Cancer (PDAC): Introduction of Evidence-Based Complementary Measures into Integrative Clinical Management.
Jentzsch V, Davis JAA, Djamgoz MBA. Jentzsch V, et al. Cancers (Basel). 2020 Oct 23;12(11):3096. doi: 10.3390/cancers12113096. Cancers (Basel). 2020. PMID: 33114159 Free PMC article. Review.
Using wearable biological sensors to provide personalized feedback to motivate behavioral changes: Study protocol for a randomized controlled physical activity intervention in cancer survivors (Project KNOWN).
Liao Y, Schembre SM, Brannon GE, Pan Z, Wang J, Ali S, Beg MS, Basen-Engquist KM. Liao Y, et al. PLoS One. 2022 Sep 13;17(9):e0274492. doi: 10.1371/journal.pone.0274492. eCollection 2022. PLoS One. 2022. PMID: 36099282 Free PMC article.
A Mathematical Model of the Disruption of Glucose Homeostasis in Cancer Patients.
Salentine N, Doria J, Nguyen C, Pinter G, Wang SE, Hinow P. Salentine N, et al. Bull Math Biol. 2023 May 27;85(7):58. doi: 10.1007/s11538-023-01146-3. Bull Math Biol. 2023. PMID: 37243841 Free PMC article.
Pancreatic Cancer: An Exocrine Tumor With Endocrine Characteristics.
Zhu X, Xiao Z, Liu H, Zhang P, Deng S, Ding L, Feng J, Luo J, Ni Q, Luo G, Yu X. Zhu X, et al. Ann Surg. 2024 Dec 1;280(6):e17-e25. doi: 10.1097/SLA.0000000000006168. Epub 2023 Dec 5. Ann Surg. 2024. PMID: 38050737 Free PMC article. Clinical Trial.
GLR in Colorectal Cancers: An Easily Accessible Prognostic Marker.
Aydin İC, Subasi IE, Sunar AO, Ademoglu S, Gulmez S, Dincer M, Duman M, Polat E. Aydin İC, et al. Int J Gen Med. 2024 May 22;17:2361-2369. doi: 10.2147/IJGM.S463769. eCollection 2024. Int J Gen Med. 2024. PMID: 38799200 Free PMC article.

Non-diabetic Glucose levels and Cancer Mortality: A Literature Review - PubMed